In amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic mice, a widely used preclinical model of AD, systemic leptin treatment increased Iba1+ microglial activation, consistent with a role for leptin in modulating microglial responses in vivo. The gene discussed is LEP; the disease is Alzheimer disease.